AAPL307.92+13.54 (+4.60%) ▲|ABBV258.75+7.69 (+3.06%) ▲|ABT95.06+2.88 (+3.12%) ▲|ACN137.59+6.46 (+4.93%) ▲|ADBE221.29+10.31 (+4.89%) ▲|AMAT582.22-68.69 (-10.55%) ▼|AMD508.29-32.59 (-6.03%) ▼|AMGN370.97+9.64 (+2.67%) ▲|AMT167.10+1.02 (+0.61%) ▲|AMZN244.18+2.48 (+1.02%) ▲|AVGO358.48-10.86 (-2.94%) ▼|AXP349.14+2.09 (+0.60%) ▲|BA223.36+4.78 (+2.19%) ▲|BAC58.41+0.05 (+0.08%) ▲|BKNG182.11-0.53 (-0.29%) ▼|BLK990.65+10.27 (+1.05%) ▲|BMY57.13+1.32 (+2.36%) ▲|BNY145.30-0.72 (-0.49%) ▼|BRK-B505.86+6.12 (+1.22%) ▲|C138.41-1.72 (-1.23%) ▼|CAT952.74-38.67 (-3.90%) ▼|CL94.85+2.09 (+2.25%) ▲|CMCSA23.33-0.41 (-1.71%) ▼|COF203.34-1.48 (-0.72%) ▼|COP103.65+0.43 (+0.41%) ▲|COST948.52+23.85 (+2.58%) ▲|CRM165.63+2.40 (+1.47%) ▲|CSCO112.42-4.60 (-3.93%) ▼|CVS103.51-1.30 (-1.24%) ▼|CVX168.28+2.59 (+1.56%) ▲|DE616.89-10.75 (-1.71%) ▼|DHR196.52+2.80 (+1.45%) ▲|DIS98.04+2.33 (+2.43%) ▲|DUK128.25+2.48 (+1.97%) ▲|EMR137.50-2.02 (-1.45%) ▼|FDX311.28-2.61 (-0.83%) ▼|GD369.77+8.50 (+2.35%) ▲|GE374.86-0.08 (-0.02%) ▼|GEV1,096.07-38.29 (-3.38%) ▼|GILD129.82+3.85 (+3.05%) ▲|GM74.40-1.12 (-1.49%) ▼|GOOG353.34-4.55 (-1.27%) ▼|GOOGL356.52-4.70 (-1.30%) ▼|GS1,011.89-7.73 (-0.76%) ▼|HD354.31+3.47 (+0.99%) ▲|HON226.01+4.26 (+1.92%) ▲|IBM285.80-0.45 (-0.16%) ▼|INTC119.47-7.55 (-5.94%) ▼|INTU275.16+8.08 (+3.03%) ▲|ISRG421.27+18.89 (+4.69%) ▲|JNJ261.48+7.50 (+2.95%) ▲|JPM332.72-1.35 (-0.40%) ▼|KO83.07+1.78 (+2.18%) ▲|LIN545.31+11.76 (+2.20%) ▲|LLY1,207.93+16.19 (+1.36%) ▲|LMT537.11+15.29 (+2.93%) ▲|LOW224.59+2.67 (+1.20%) ▲|LRCX346.53-44.73 (-11.43%) ▼|MA536.68+14.24 (+2.73%) ▲|MCD278.21+8.78 (+3.26%) ▲|MDLZ60.43+1.08 (+1.82%) ▲|MDT82.49+3.29 (+4.15%) ▲|META584.66-28.25 (-4.61%) ▼|MMM159.84-0.13 (-0.08%) ▼|MO72.28+0.74 (+1.03%) ▲|MRK128.13+2.76 (+2.20%) ▲|MS212.02+0.16 (+0.08%) ▲|MSFT390.75+6.47 (+1.68%) ▲|MU962.11-70.17 (-6.80%) ▼|NEE87.29+0.92 (+1.06%) ▲|NFLX78.19+4.00 (+5.39%) ▲|NKE43.95+0.89 (+2.07%) ▲|NOW106.02+0.22 (+0.21%) ▲|NVDA193.10-4.48 (-2.27%) ▼|ORCL139.27-3.23 (-2.27%) ▼|PEP143.74+2.58 (+1.83%) ▲|PFE24.28+0.40 (+1.65%) ▲|PG151.04+3.61 (+2.45%) ▲|PLTR131.35+5.62 (+4.47%) ▲|PM180.47+2.78 (+1.56%) ▲|QCOM173.30-8.62 (-4.74%) ▼|RTX196.72+4.94 (+2.58%) ▲|SBUX104.01+0.62 (+0.60%) ▲|SCHW96.54+0.76 (+0.79%) ▲|SO97.26+2.14 (+2.25%) ▲|SPG224.69+1.69 (+0.76%) ▲|T20.12-0.37 (-1.78%) ▼|TMO520.06+6.73 (+1.31%) ▲|TMUS174.81+1.75 (+1.01%) ▲|TSLA392.09-33.22 (-7.81%) ▼|TXN289.85-8.57 (-2.87%) ▼|UBER73.36+0.70 (+0.96%) ▲|UNH422.34-4.20 (-0.98%) ▼|UNP280.32+2.59 (+0.93%) ▲|UPS109.48-0.07 (-0.06%) ▼|USB61.30-0.66 (-1.07%) ▼|V359.66+8.58 (+2.44%) ▲|VZ41.48-0.52 (-1.23%) ▼|WFC85.18-0.76 (-0.88%) ▼|WMT111.84+3.02 (+2.77%) ▲|XOM136.93+0.65 (+0.48%) ▲|AAPL307.92+13.54 (+4.60%) ▲|ABBV258.75+7.69 (+3.06%) ▲|ABT95.06+2.88 (+3.12%) ▲|ACN137.59+6.46 (+4.93%) ▲|ADBE221.29+10.31 (+4.89%) ▲|AMAT582.22-68.69 (-10.55%) ▼|AMD508.29-32.59 (-6.03%) ▼|AMGN370.97+9.64 (+2.67%) ▲|AMT167.10+1.02 (+0.61%) ▲|AMZN244.18+2.48 (+1.02%) ▲|AVGO358.48-10.86 (-2.94%) ▼|AXP349.14+2.09 (+0.60%) ▲|BA223.36+4.78 (+2.19%) ▲|BAC58.41+0.05 (+0.08%) ▲|BKNG182.11-0.53 (-0.29%) ▼|BLK990.65+10.27 (+1.05%) ▲|BMY57.13+1.32 (+2.36%) ▲|BNY145.30-0.72 (-0.49%) ▼|BRK-B505.86+6.12 (+1.22%) ▲|C138.41-1.72 (-1.23%) ▼|CAT952.74-38.67 (-3.90%) ▼|CL94.85+2.09 (+2.25%) ▲|CMCSA23.33-0.41 (-1.71%) ▼|COF203.34-1.48 (-0.72%) ▼|COP103.65+0.43 (+0.41%) ▲|COST948.52+23.85 (+2.58%) ▲|CRM165.63+2.40 (+1.47%) ▲|CSCO112.42-4.60 (-3.93%) ▼|CVS103.51-1.30 (-1.24%) ▼|CVX168.28+2.59 (+1.56%) ▲|DE616.89-10.75 (-1.71%) ▼|DHR196.52+2.80 (+1.45%) ▲|DIS98.04+2.33 (+2.43%) ▲|DUK128.25+2.48 (+1.97%) ▲|EMR137.50-2.02 (-1.45%) ▼|FDX311.28-2.61 (-0.83%) ▼|GD369.77+8.50 (+2.35%) ▲|GE374.86-0.08 (-0.02%) ▼|GEV1,096.07-38.29 (-3.38%) ▼|GILD129.82+3.85 (+3.05%) ▲|GM74.40-1.12 (-1.49%) ▼|GOOG353.34-4.55 (-1.27%) ▼|GOOGL356.52-4.70 (-1.30%) ▼|GS1,011.89-7.73 (-0.76%) ▼|HD354.31+3.47 (+0.99%) ▲|HON226.01+4.26 (+1.92%) ▲|IBM285.80-0.45 (-0.16%) ▼|INTC119.47-7.55 (-5.94%) ▼|INTU275.16+8.08 (+3.03%) ▲|ISRG421.27+18.89 (+4.69%) ▲|JNJ261.48+7.50 (+2.95%) ▲|JPM332.72-1.35 (-0.40%) ▼|KO83.07+1.78 (+2.18%) ▲|LIN545.31+11.76 (+2.20%) ▲|LLY1,207.93+16.19 (+1.36%) ▲|LMT537.11+15.29 (+2.93%) ▲|LOW224.59+2.67 (+1.20%) ▲|LRCX346.53-44.73 (-11.43%) ▼|MA536.68+14.24 (+2.73%) ▲|MCD278.21+8.78 (+3.26%) ▲|MDLZ60.43+1.08 (+1.82%) ▲|MDT82.49+3.29 (+4.15%) ▲|META584.66-28.25 (-4.61%) ▼|MMM159.84-0.13 (-0.08%) ▼|MO72.28+0.74 (+1.03%) ▲|MRK128.13+2.76 (+2.20%) ▲|MS212.02+0.16 (+0.08%) ▲|MSFT390.75+6.47 (+1.68%) ▲|MU962.11-70.17 (-6.80%) ▼|NEE87.29+0.92 (+1.06%) ▲|NFLX78.19+4.00 (+5.39%) ▲|NKE43.95+0.89 (+2.07%) ▲|NOW106.02+0.22 (+0.21%) ▲|NVDA193.10-4.48 (-2.27%) ▼|ORCL139.27-3.23 (-2.27%) ▼|PEP143.74+2.58 (+1.83%) ▲|PFE24.28+0.40 (+1.65%) ▲|PG151.04+3.61 (+2.45%) ▲|PLTR131.35+5.62 (+4.47%) ▲|PM180.47+2.78 (+1.56%) ▲|QCOM173.30-8.62 (-4.74%) ▼|RTX196.72+4.94 (+2.58%) ▲|SBUX104.01+0.62 (+0.60%) ▲|SCHW96.54+0.76 (+0.79%) ▲|SO97.26+2.14 (+2.25%) ▲|SPG224.69+1.69 (+0.76%) ▲|T20.12-0.37 (-1.78%) ▼|TMO520.06+6.73 (+1.31%) ▲|TMUS174.81+1.75 (+1.01%) ▲|TSLA392.09-33.22 (-7.81%) ▼|TXN289.85-8.57 (-2.87%) ▼|UBER73.36+0.70 (+0.96%) ▲|UNH422.34-4.20 (-0.98%) ▼|UNP280.32+2.59 (+0.93%) ▲|UPS109.48-0.07 (-0.06%) ▼|USB61.30-0.66 (-1.07%) ▼|V359.66+8.58 (+2.44%) ▲|VZ41.48-0.52 (-1.23%) ▼|WFC85.18-0.76 (-0.88%) ▼|WMT111.84+3.02 (+2.77%) ▲|XOM136.93+0.65 (+0.48%) ▲|
37.8 C
New York
Thursday, July 2, 2026

Tag: stage

newssourceFORcompanyinformationcontent1releasesmarket

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Construct including CT domain demonstrated higher levels of microdystrophin protein, increased muscle force, and improved resistance to damage in mice lacking dystrophin REGENXBIO's next-generation...

Global Bioenergies: takeover bid deadline extended to 18 July 2025

PRESS RELEASE

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM)NEW YORK and NORTH CHICAGO, Ill., July 10, 2025...

Proven Nurse Leadership Program Now Open to the Public for the First Time

VERO BEACH, Fla., July 10, 2025 /PRNewswire/ -- As healthcare systems continue to face high turnover, burnout, and operational strain, Inspire Nurse Leaders® is proud...

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer rates are...

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer rates are...

Worksport Reports Q2 2025 Top-Line Revenue, Signals Profitability on Horizon with Expanding Margins and Product Momentum

Company Achieves Breakout Quarter as Turnaround Strategy Gains Traction; Clean-Tech Product Launches Poised to Accelerate Growth

NANO Nuclear to Participate in Fireside Chat at H.C. Wainwright’s Powering the Future: Advancing Innovation Through Nuclear Virtual Conference on July 15th

New York, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that Chief Executive Officer James Walker will participate in a fireside chat at H.C. Wainwright’s Powering the Future: Advancing Innovation Through Nuclear Virtual Conference hosted by Sameer Joshi, Senior Cleantech Analyst at H.C. Wainwright, on July 15, 2025 at 9:00 a.m., Eastern time.

SolarBank Issues Update on Strategic Positioning Amid Shifting U.S. and Canadian Policy Landscape

TORONTO, July 10, 2025 /CNW/ - SolarBank Corporation (Cboe CA: SUNN) (NASDAQ: SUUN) ("SolarBank" or the "Company"), a leading North American developer, owner, and operator of...

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at...

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentations include a cost savings analysis of the use of pTau217 as a screening tool in Acumen’s Phase 2 ALTITUDE-AD trial of sabirnetug as well as a nonclinical study evaluating the relative selectivity of sabirnetug to targeting AβOs versus Aβ monomers. The conference will be held July 27-31, 2025, both in-person and online.

Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody

MIDDLETOWN, Del., July 10, 2025 /PRNewswire/ -- Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase...

TCL CSOT Display Technology Sets New Trend in Foldables with Lenovo moto razr 60 Series

SHANGHAI, July 10, 2025 /PRNewswire/ -- TCL CSOT, a global leader in advanced display technologies, participated in the Lenovo Tianxi AI Ecosystem Spring Launch...

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026 
Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026

Orla Mining Achieves Record Quarterly Production with First Full Quarter Contribution from Musselwhite

VANCOUVER, BC, July 10, 2025 /CNW/ - Orla Mining Ltd. (TSX: OLA) (NYSE: ORLA) ("Orla" or the "Company") is pleased to provide an operational...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStage

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers